Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Mimedx (MDXG) EBIT Margin (2016 - 2025)

Mimedx (MDXG) has disclosed EBIT Margin for 15 consecutive years, with 17.85% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 595.0% to 17.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 15.26% through Dec 2025, down 161.0% year-over-year, with the annual reading at 15.26% for FY2025, 161.0% down from the prior year.
  • EBIT Margin hit 17.85% in Q4 2025 for Mimedx, down from 19.51% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 26.89% in Q2 2024 to a low of 15.79% in Q1 2022.
  • Historically, EBIT Margin has averaged 6.73% across 5 years, with a median of 12.22% in 2025.
  • Biggest five-year swings in EBIT Margin: surged 2775bps in 2023 and later crashed -1435bps in 2025.
  • Year by year, EBIT Margin stood at 2.53% in 2021, then soared by 501bps to 15.21% in 2022, then increased by 17bps to 17.84% in 2023, then plummeted by -33bps to 11.9% in 2024, then skyrocketed by 50bps to 17.85% in 2025.
  • Business Quant data shows EBIT Margin for MDXG at 17.85% in Q4 2025, 19.51% in Q3 2025, and 12.55% in Q2 2025.